These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14970853)

  • 21. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
    Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
    Brock CS; Young H; O'Reilly SM; Matthews J; Osman S; Evans H; Newlands ES; Price PM
    Br J Cancer; 2000 Feb; 82(3):608-15. PubMed ID: 10682673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent advances in the medical treatment of glioma-temozolomide].
    Nishikawa R
    No To Shinkei; 2006 Dec; 58(12):1035-41. PubMed ID: 17193953
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
    Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
    J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of temozolomide in patients with progressive low-grade glioma.
    Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Provenzale JM; McLendon RE; Gururangan S; Bigner DD; Herndon JE; Avgeropoulos N; Finlay J; Tourt-Uhlig S; Affronti ML; Evans B; Stafford-Fox V; Zaknoen S; Friedman HS
    J Clin Oncol; 2003 Feb; 21(4):646-51. PubMed ID: 12586801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of temozolomide treatment for patients with glioma.
    Yang WB; Xing BZ; Liang H
    Asian Pac J Cancer Prev; 2014; 15(19):8405-8. PubMed ID: 25339037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
    Bower M; Newlands ES; Bleehen NM; Brada M; Begent RJ; Calvert H; Colquhoun I; Lewis P; Brampton MH
    Cancer Chemother Pharmacol; 1997; 40(6):484-8. PubMed ID: 9332462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
    Mäenpää HO; Aaltonen K; Mäntylä R; Minn H
    Acta Oncol; 2004; 43(6):579-84. PubMed ID: 15370616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral administration of choline does not affect metabolic characteristics of gliomas and normal-appearing white matter, as detected with single-voxel (1)H-MRS at 1.5 T.
    Chernov MF; Muragaki Y; Maruyama T; Ono Y; Usukura M; Yoshida S; Nakamura R; Iseki H; Kubo O; Hori T; Takakura K
    Neuroradiology; 2009 Mar; 51(3):137-43. PubMed ID: 18949472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and future developments in the use of temozolomide for the treatment of brain tumours.
    Stupp R; Gander M; Leyvraz S; Newlands E
    Lancet Oncol; 2001 Sep; 2(9):552-60. PubMed ID: 11905710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential biochemical therapy of glioma cancer.
    Yin LT; Fu YJ; Xu QL; Yang J; Liu ZL; Liang AH; Fan XJ; Xu CG
    Biochem Biophys Res Commun; 2007 Oct; 362(2):225-9. PubMed ID: 17707767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
    Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
    J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Temozolomide in the treatment of recurrent malignant glioma].
    Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
    No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is protracted low-dose temozolomide feasible in glioma patients?
    Wong ET
    Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
    [No Abstract]   [Full Text] [Related]  

  • 37. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
    Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
    Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
    Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
    Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
    Friedman HS
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):35-40. PubMed ID: 10866348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is protracted low-dose temozolomide feasible in glioma patients?
    Tosoni A; Cavallo G; Ermani M; Scopece L; Franceschi E; Ghimenton C; Gardiman M; Pasetto L; Blatt V; Brandes AA
    Neurology; 2006 Feb; 66(3):427-9. PubMed ID: 16476947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.